학술논문
iStent inject trabecular microbypass stent implantation with cataract extraction in open-angle glaucoma: early clinical experience.
Document Type
Academic Journal
Author
Ferguson TJ; Cole Eye Institute, Cleveland Clinic, Cleveland, OH USA.; Dockter Z; University of South Dakota Sanford School of Medicine, Sioux Falls, SD USA.; Bleeker A; University of South Dakota Sanford School of Medicine, Sioux Falls, SD USA.; Karpuk KL; Cleveland Eye Clinic, Cleveland, OH USA.; Schweitzer J; Vance Thompson Vision, Sioux Falls, SD USA.; Ibach MJ; Vance Thompson Vision, Sioux Falls, SD USA.; Berdahl JP; Vance Thompson Vision, Sioux Falls, SD USA.
Source
Publisher: BioMed Central Country of Publication: England NLM ID: 101664982 Publication Model: eCollection Cited Medium: Print ISSN: 2326-0254 (Print) Linking ISSN: 23260254 NLM ISO Abbreviation: Eye Vis (Lond) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2326-0254
Abstract
Background: Retrospective, consecutive case series to evaluate the implantation of two second-generation trabecular microbypass stents in combination with cataract surgery in a real-world, clinical setting.
Methods: The series included 56 eyes implanted with the iStent inject device with phacoemulsification. The series consisted of eyes with primary open-angle glaucoma ( n = 52) and pseudoexfoliative glaucoma ( n = 4). Primary outcome measures included intraocular pressure (IOP) and number of glaucoma medications. Safety outcomes included the need for secondary surgical intervention and the incidence of IOP spikes ≥10 mmHg and ≥ 15 mmHg.
Results: IOP was reduced by 21% to 14.7 ± 2.9 mmHg ( p < 0.01) at 6 months postoperative from 18.7 ± 5.8 mmHg at baseline. Preoperatively, the mean number of glaucoma medications was 1.5 ± 0.9 and reduced by 39% to 0.9 ± 1.2 ( p < 0.01) at 6 months. At 6 months, 68% of eyes had an IOP ≤15 mmHg, increased from 30% at baseline. 55% of eyes were medication-free at 6 months, up from 18% at baseline. There were no severe postoperative complications. No eyes underwent an additional glaucoma procedure.
Conclusions: Implantation of the iStent inject device with concomitant cataract surgery effectively provides a sustained reduction in IOP with a markedly improved medication burden out to 6 months postoperative. The safety profile is excellent.
Competing Interests: Competing interestsDrs. Ferguson, Schweitzer, Ibach and Berdahl are speakers and consultants for Glaukos Corporation.
(© The Author(s) 2020.)
Methods: The series included 56 eyes implanted with the iStent inject device with phacoemulsification. The series consisted of eyes with primary open-angle glaucoma ( n = 52) and pseudoexfoliative glaucoma ( n = 4). Primary outcome measures included intraocular pressure (IOP) and number of glaucoma medications. Safety outcomes included the need for secondary surgical intervention and the incidence of IOP spikes ≥10 mmHg and ≥ 15 mmHg.
Results: IOP was reduced by 21% to 14.7 ± 2.9 mmHg ( p < 0.01) at 6 months postoperative from 18.7 ± 5.8 mmHg at baseline. Preoperatively, the mean number of glaucoma medications was 1.5 ± 0.9 and reduced by 39% to 0.9 ± 1.2 ( p < 0.01) at 6 months. At 6 months, 68% of eyes had an IOP ≤15 mmHg, increased from 30% at baseline. 55% of eyes were medication-free at 6 months, up from 18% at baseline. There were no severe postoperative complications. No eyes underwent an additional glaucoma procedure.
Conclusions: Implantation of the iStent inject device with concomitant cataract surgery effectively provides a sustained reduction in IOP with a markedly improved medication burden out to 6 months postoperative. The safety profile is excellent.
Competing Interests: Competing interestsDrs. Ferguson, Schweitzer, Ibach and Berdahl are speakers and consultants for Glaukos Corporation.
(© The Author(s) 2020.)